Recent findings demonstrate that NF-κB regulates chemotherapy resistance in various tumors, including gastric cancer [81,82], CRC [83], NSCLC [84,85,86], pancreatic ductal adenocarcinoma (PDAC) [87], breast cancer [88,89,90,91,92], prostate cancer [93], GBM [94,95], and hematological tumors [96,97,98,99]. Here, NFKB1 is linked to colorectal carcinoma.